Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24198771 | 0.84 | POLB (0.50) | HCAR2CYP2C19HTTRAB9AEGFR | |
| SCHEMBL24198736 | 0.82 | HCAR2 (0.55) | HCAR2ATMSMYD3CYP2C19CYP2C9 | |
| SCHEMBL24198695 | 0.81 | DDR1 (0.42) | ACKR3CYP1A2CYP3A4POLB | |
| SCHEMBL18994707 | 0.78 | HPGD (0.47) | CYP2C19POLB | |
| SCHEMBL8237840 | 0.78 | HCAR2 (0.62) | HCAR2ATMSMYD3CYP2C19CYP2C9 | |
| SCHEMBL10274533 | 0.75 | HCAR2 (0.58) | HCAR2ATMSMYD3CYP2C19CYP2C9 | |
| SCHEMBL21919758 | 0.73 | CA5A (0.36) | — | |
| SCHEMBL24435634 | 0.73 | SERPINE1 (0.45) | HTTKDM4EPOLB | |
| SCHEMBL3473330 | 0.73 | HCAR2 (0.60) | HCAR2ATMSMYD3HTTRAB9A | |
| SCHEMBL24198754 | 0.72 | HCAR2 (0.55) | HCAR2SMYD3CYP2C19CYP2C9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | HCAR2 4422/4885ATM 3043/4885SMYD3 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.